This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

GUER.F Stock Overview

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. More details

GUER.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	5/6
Dividends	6/6

Rewards

Trading at 64.8% below our estimate of its fair value

Earnings are forecast to grow 28.39% per year

Pays a high and reliable dividend of 5.25%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Profit margins (1.7%) are lower than last year (4.7%)

My Notes

Capture your thoughts, links and company narrative

Guerbet SA Competitors

Utah Medical Products

NasdaqGS:UTMD

US$204.2m

Xtant Medical Holdings

NYSEAM:XTNT

US$77.8m

Atrion

NasdaqGS:ATRI

US$809.4m

Embecta

NasdaqGS:EMBC

US$819.7m

Price History & Performance

Summary of share price highs, lows and changes for Guerbet
Historical stock prices
Current Share Price	€22.25
52 Week High	€32.00
52 Week Low	€22.25
Beta	0.76
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-90.17%

Recent updates

Shareholder Returns

	GUER.F	US Medical Equipment	US Market
7D	0%	-0.3%	-2.2%
1Y	n/a	10.0%	18.3%

Return vs Industry: Insufficient data to determine how GUER.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how GUER.F performed against the US Market.

Price Volatility

Is GUER.F's price volatile compared to industry and market?
GUER.F volatility
GUER.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	17.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GUER.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GUER.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1926	2,730	David Hale	www.guerbet.com

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.

Guerbet SA Fundamentals Summary

How do Guerbet's earnings and revenue compare to its market cap?
GUER.F fundamental statistics
Market cap	US$200.56m
Earnings (TTM)	US$12.34m
Revenue (TTM)	US$731.03m

16.3x

P/E Ratio

0.3x

P/S Ratio

Is GUER.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GUER.F income statement (TTM)
Revenue	€745.50m
Cost of Revenue	€214.57m
Gross Profit	€530.93m
Other Expenses	€518.35m
Earnings	€12.59m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	1.00
Gross Margin	71.22%
Net Profit Margin	1.69%
Debt/Equity Ratio	67.5%

How did GUER.F perform over the long term?

See historical performance and comparison

Dividends

5.2%

Current Dividend Yield

86%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/10/02 19:49
End of Day Share Price	2022/07/05 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guerbet SA is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Laurent Gelebart	BNP Paribas Exane
Arnaud Cadart	CIC Market Solutions (ESN)
Robin Leclerc	Degroof Petercam